Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report

Shetal A Patel; Young Whang; Chaely Medley; Kevin Chen; Jasmine Jordan; Dante Bortone; Benjamin Vincent; Jared Weiss

doi:10.1016/j.jtocrr.2024.100712

Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report

JTO Clin Res Rep. 2024 Jul 31;5(10):100712. doi: 10.1016/j.jtocrr.2024.100712. eCollection 2024 Oct.

Authors

Shetal A Patel^{1

2}, Young Whang^{1

2}, Chaely Medley², Kevin Chen³, Jasmine Jordan¹, Dante Bortone¹, Benjamin Vincent¹, Jared Weiss^{1

2}

Affiliations

¹ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
² Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
³ Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina.

Abstract

A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3-targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome but resulted in a partial response. Bispecific T cell engagers may offer a novel treatment approach for large cell neuroendocrine carcinoma of the lung.

Keywords: Bispecific T-cell engager; Case report; Cytokine release syndrome; DLL3; Large cell neuroendocrine carcinoma; Tarlatamab.

Publication types

Case Reports